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Irregular functioning of cysteine proteinases cathepsin (Cath) B, H
and L has been proposed as being involved in the development of
various diseases, including cancer (Sloane et al, 1994; Schmitt et
al, 1995; Duffy et al, 1996; Kos et al, 1998). Numerous studies
have demonstrated a correlation of increased proteolytic activity
of cysteine cathepsins with neoplastic transformation, tumour
invasion and metastasis. Furthermore, the levels of these enzymes
in tumours and some extracellular fluids have been shown to allow
the disease-free and overall survival period to be predicted and
therefore may serve as prognostic factors for cancer patients.
However, the investigations were mainly focused on Cath B and
Cath L, whereas the role of Cath H in malignant progression was
much less studied and remains contradictory.
Increased levels of Cath H have been observed in glioblastoma
and anaplastic astrocytoma when compared with normal brain
tissue and low-grade gliomas (Sivaparvathi et al, 1996). Higher
levels were also found in tumour tissue and sera of patients with
breast cancer (Gabrijelc ˘ic ˘ et al, 1992) and in sera of melanoma
patients (Kos et al, 1997). However, in head and neck tumours the
levels of Cath H were lower in tumour tissue when compared to
adjacent control tissue (Kos et al, 1995). Moreover, the lower
levels of Cath H were associated with shorter disease-free survival
period (Budihna et al, 1996). In the same study the opposite was
true for Cath B and Cath L.
Cath H has also been shown to be a prognostic marker in
melanoma patients. Patients with high serum levels of Cath H
experienced significantly shorter overall survival than patients
with low levels of the enzyme (Kos et al, 1997). In addition it was
shown to predict the effectiveness of chemoimmunotherapy
exhibiting significantly higher levels in non-responders than in
responders (Kos et al, 1997).
In lung carcinoma the behaviour of Cath H has not so far been
studied, although increased activity and/or concentrations of Cath
B (Treftz et al, 1989; Krepela et al, 1990; Ebert et al, 1994; Knoch
et al, 1994; Ledakis et al, 1996, Werle et al, 1997a), Cath L
(Ledakis et al, 1996; Werle et al, 1997a) and Cath S (Werle et al,
1999b) are well documented in lung tumour cytosols and tissue
sections. Higher levels of Cath B activity (Ebert et al, 1994) and of
Cath L protein (Werle et al, 1997a) were found to correlate with
shorter survival of patients with lung carcinoma.
The aim of the present study was to determine the levels of Cath
H in lung tumours and their surrounding histologically non-
cancerous lung parenchyma. Additionally, the levels of Cath H
were determined in sera of patients with histologically distinct
lung tumours and compared to controls. Results have been related
to histopathological and clinical features, considering especially
the correlation of individual tumour levels of Cath H with survival
and with the smoking history of patients.
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Summary In order to evaluate the role of cysteine peptidase cathepsin H (Cath H) in human lung cancer its protein levels were determined in
148 pairs of lung tumour tissue and adjacent non-tumourous lung parenchyma using the enzyme-linked immunosorbent assay technique.
Additionally, Cath H levels were determined in sera of 171 patients with malignant tumours, 34 patients with benign lung diseases and 47
healthy controls. The median level of Cath H in tumour tissue was 0.64 times that in the corresponding lung parenchyma. Relating tumour
levels with histological type we found higher Cath H levels in small-cell and adenocarcinomas and lower levels in squamous cell carcinoma,
large-cell carcinoma and secondary tumours. A significant difference in Cath H level between lung tumour tissue and non-tumourous lung
parenchyma was associated with the group of cigarette smokers (156 vs 263 ng mg–1 protein, P < 0.001). For this group of patients Cath H
tumour levels correlated with the survival rate, while for the entire patient population this was not the case. Smokers with high tumour levels
of Cath H experienced poor survival. Cath H was significantly higher in sera of patients with malignant and benign lung diseases than in
control sera (P < 0.001). The increase was significant for all histological types, being the highest in small-cell and squamous cell carcinomas.
Our study reveals that in lung tumours there is different behaviour of Cath H compared with other cysteine peptidases, e.g. cathepsin B and
cathepsin L. Variations between tissue and serum levels of Cath H indicate either reduced expression or enhanced secretion of this enzyme
in lung tumours. © 2000 Cancer Research Campaign
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Patients
Lung tumour tissue and adjacent control (non-cancerous) lung
parenchyma were obtained as matched paired samples from 148
lung cancer patients treated by surgery at the Thoraxhospital
Heidelberg-Rohrbach. The age of patients in this group ranged
from 15 to 78 (median 60). A major proportion were smokers 
(n = 90, 60.8%), 17 (11.5%) were ex-smokers, having stopped
smoking at least 0.25 years before surgery, 41 (27.7%) were non-
smokers, or stopped smoking at least 5 years before surgery. The
cell type of lung cancer was classified according to the WHO
protocol and was based on predominant cell type (World Health
Organization, 1981). The tumour disease stage (pTNM) was 
classified according to the international staging system (Hermanek
and Sobin, 1987).
The second group of patients consisted of 171 patients with
malignant tumours and 34 patients with benign diseases included
in an ongoing prospective study on prognostic values of extracel-
lular cysteine peptidases and their inhibitors in lung cancer. From
patients’ malignant tumours only Cath H post-therapy serum
levels were included in the study. The median age and the range
for these patients is comparable to the previous group. Out of 171
patients with malignant tumours 60 were small-cell, 67 adeno and
44 squamous cell type. The group of patients with benign diseases
consisted of patients with pulmonary embolism, fibrosis, broncho-
stenosis, sarcoidosis, pneumonia, tuberculosis, pleuritis/emphy-
sema, congestive heart failure, actinomycosis, bronchiectases and
bronchial asthma. As a control group, sera from 47 healthy blood
donors were collected (Kos et al, 1998).
Sample collection
Tissue homogenization was carried out as described by Werle et al
(1995). Five-millilitre blood samples were collected from lung
cancer patients after therapy. The blood was clotted at 4–8°C and
centrifuged at 3000 rpm. The sera were stored at –30°C until
analysed. Sera from blood donors were sampled in a similar way.
Determination of cathepsin H
Cath H concentrations were determined by enzyme-linked
immunosorbent assay (ELISA) (sandwich ELISA; Krka d.d., Novo
mesto, Slovenia) developed at Joz ˘ef Stefan Institute (Ljubljana,
Slovenia). The components were purified and characterized, and
the test optimized as described (Schweiger et al, 1997). The sheep
polyclonal and murine 1D10 monoclonal antibodies recognize
precursor and mature forms of Cath H, as well as enzyme–inhibitor
complexes (Schweiger et al, 1997).
Linearity of the ELISA was tested by serial dilution of tissue
cytosols or sera to levels within the range of the assay (Schweiger et
al, 1997). The measured values of diluted samples were subse-
quently compared with standard values. Recovery was tested by the
addition of different amounts of antigen to samples with known
antigen concentration and was found to vary between 87.4 and
104.9%. A microplate reader (SLT Rainbow, Austria) was used to
measure absorbance in ELISA. Cath H was expressed in ng mg–1 of
total protein. The detection limit of the assay was 2 ng ml–1.
Tissue samples at 1:50 dilution and serum samples at 1:2 dilu-
tion were added to wells of a microtitre plate previously precoated
with sheep polyclonal antibody to Cath H. The assay was then
performed as described (Schweiger et al, 1997). After 2 h of incu-
bation at 37°C the wells were washed and murine 1D10 mono-
clonal antibody, purified by affinity chromatography on Protein A
Sepharose and conjugated subsequently with horseradish peroxi-
dase (HRP) was added. After a further 2 h incubation at 37°C,
peroxidase substrate 3,3,5,5-tetramethyl benzidine (TMB, Sigma,
St Louis, MO, USA) in the presence of hydrogen peroxide was
added. The amount of degraded substrate, as a measure of bound
immuno-complexed Cath H, was measured by absorbance at
450 nm and the Cath H concentration was calculated from the
calibration curve.
Protein determination
Protein concentrations were determined according to Bradford et
al (1976). Bovine serum albumin was used as standard.
Statistical analysis
The results of Cath H measurements in the group under study are
given as 5%, 50% (median) and 95% percentiles. For comparing
the data of matched pairs of tumour and lung tissue, Wilcoxon’s
rank test was used. Differences in Cath H levels (tissue and serum)
between various groups of patients were tested by Mann–Whitney
and Kruskal–Wallis test. Univariate analysis of survival proba-
bility was performed by Kaplan–Meier analysis (Kaplan and
Meier, 1958), using the log-rank test for determining statistical
significance between survival curves. Critlevel program (Abel et
al, 1984) was used for dichotomization of variables into low and
high groups. In all tests, two-sided P-values below 5% were
considered significant. Various statistical packages (SPSS
program, SPSS Inc., Illinois, USA; PC-Statistic, TOPSOFT,
Hannover, Germany; Statistica, StatSoft, Hamburg, Germany)
were used.
RESULTS
Distribution of Cath H in lung tumours and in non-
tumourous lung parenchyma
The concentrations of Cath H in 148 tissue homogenates of lung
tumours and the corresponding non-tumourous lung parenchyma
are summarized in Table 1. In the total patient population the
median of Cath H concentration in tumour tissue was 0.64 times
that in the control lung parenchyma.
The data were further analysed with respect to tumour histology,
the anatomical spread out of the tumour (pTNM-stages), the
degree of cell differentiation and smoking habits (Table 1).
Regarding tumour histology, as seen in Figure 1, we found the
lowest median value of Cath H in tumour tissues, compared to
their control lung counterparts, in large-cell carcinomas and in
squamous cell carcinomas. The ratios for both carcinomas were
significantly different (P = 0.001 and P = 0.028 respectively). In
contrast, in carcinoids (n = 5) the median level of Cath H was 
1.7-fold higher in tumour tissue than in lung parenchyma, but the
difference was not statistically significant.
The highest median value of Cath H was detected in small-
cell carcinomas (SCLC) and in adenocarcinomas (AC). While 
low numbers of SCLC (n = 3) did not permit reliable statistical
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evaluation, Cath H was significantly higher in AC than in squa-
mous cell carcinomas (SCC), in large-cell carcinomas (LCC) and
in secondary tumours (i.e. metastases to the lung). There was no
statistically significant correlation between Cath H levels and cell
differentiation, lymph node involvement and pTNM-staging.
However, in non-tumourous lung tissue significantly lower levels
of Cath H were found in patients with tumour size pT2 compared
to those with sizes pT1, pT3 and pT4 (P = 0.006, p = 0.035 and
P = 0.023 respectively).
Comparing Cath H levels in tumour tissue with those in lung
parenchyma, significant differences in patients with tumour size
pT3 and pT4 (P = 0.014 and P = 0.041 respectively), in patients
with lymph node metastasis pN1 (P = 0.001) and in patients with
pTNM-stage I, II, IIIa and pTNM-stage IIIb, IV (P = 0.005 and 
P = 0.01 respectively) are seen.
With regard to smoking habits, Cath H levels of non-tumourous
lung parenchyma were significantly higher in smokers than in 
non-smokers (P = 0.042) and are shown in Figure 2. There were
Table 1 Cathepsin H in lung tumour homogenates
Cathepsin H concentration
(ng mg-1 protein)
n Tumour median Lung median Tu/Lu P
(5%, 95%) (5%, 95%) median
Total 148 161 253 0.64 NS
(45, 864) (33, 767)
SCC 58 141 255 0.55 0.001
(46, 824) (44, 824)
AC 56 221 264 0.84 NS
(51, 1404) (25, 836)
LC 6 93 325 0.29 0.028
(72, 407) (209, 528)
Carcinoid 5 134 78 1.7 NS
(23, 690) (25, 396)
Others 1 102 207 0.49 ND
(102, 102) (207, 207)
SCLC 3 233 287 0.81 NS
(43, 398) (62, 635)
Secondary tumours 19 126 150 0.84 NS
(18, 685) (69, 1344)
pT1 19 156 339 NS
(47, 3306) (17, 2266)
pT2 79 155 211a NS
(44, 820) (30, 685)
pT3 20 162 317 0.014
(45, 1496) (15, 685)
pT4 11 244 591 0.041
(61, 988) (89, 1061)
pN0 43 173 259 NS
(37, 971) (19, 871)
pN1 41 119 253 0.001
(44, 729) (47, 812)
pN2 26 206 335 NS
(65, 1772) (80, 694)
pN3 19 168 287 NS
(53, 3306) (10, 1061)
G1/G2b 41 191 248 NS
(30, 1296) (27, 772)
G3 104 142 248 NS
(46, 799) (46, 807)
pTNMI/II/IIIa 93 157 259 0.005
(45, 844) (28, 697)
pTNMIII/b/IV 55 166 226 0.016
(46, 1054) (65, 927)
Smokers 90 156 263 0.001
(44, 1032) (33, 856)
Ex-smokers 17 164 260 0.039
(53, 901) (32, 781)
Non-smokers 41 173 181 NS
(31, 683) (30, 740)
NSCLC: non small cell lung carcinoma; SCC: squamous cell carcinoma; AC: adenocarcinoma; LC: large cell
carcinoma; SCLC: small-cell lung cancer; Tu: tumour tissue; Lu: lung parenchyma; a Cath H concentrations in normal
lung parenchyma were significantly lower in pT2 stage as compared to other stages (P = 0.004); bCell differentiation
could not be assessed for three patients; NS (not significant); ND (not determined).also significant differences in Cath H levels between non-
tumourous lung parenchyma and lung tumour tissue in smokers (P
< 0.001) and ex-smokers (P = 0.039), whereas for non-smokers no
significant differences could be observed.
Detection of Cath H in sera of patients with lung
tumours
The levels of Cath H measured in 205 serum samples from patients
suffering from lung diseases and from 47 healthy humans are
listed in Figure 3. Compared to healthy controls, the level of Cath
H was significantly increased in sera of lung cancer patients
regardless of their histological type (P < 0.001). The highest levels
were observed in SCLC and in SCC. The levels of both histo-
logical types were significantly higher than those from patients
suffering from benign lung diseases (P = 0.019 and P = 0.0003
respectively).
Survival analysis
Analysis of the entire patient population revealed no significant
correlation between Cath H levels and overall survival probability.
However, within the subgroup of smokers, Cath H levels corre-
lated with survival probability, since 11 out of 18 patients with
Cath H levels above 349 ng mg–1 died in the observation period of
4.6 years compared to 29 out of 68 patients below that cut-off level
(Figure 4). For the subgroup of non-smokers the correlation of
Cath H with overall survival probability was not significant.
DISCUSSION
In our study on 148 patients with lung carcinomas we found levels
of Cath H concentration in tumour tissue 0.64 times those from adja-
cent lung parenchyma. A similar observation has been reported for
head and neck carcinoma (Kos et al, 1995; Budihna et al, 1996) with
0.42 times lower Cath H levels in tumour tissue than in controls.
Relating tumour tissue levels of Cath H with histological cell
type we found significantly higher Cath H levels in SCLC and AC
than in SCC, LC and secondary tumours. There was no correlation
of Cath H tumour level with tumour size, lymph node involve-
ment, pTNM-stage and cell differentiation (grading).
Rather high levels of Cath H were found in non-tumourous lung
parenchyma of patients with LC, whereas the lowest levels of Cath
H were observed in pulmonary carcinoids. It should be noted that
LC are high-grade neoplasms, whereas pulmonary carcinoids are
low-grade neoplasms, with 5-year overall survival rates of about
11% and 70%, respectively (McCaughan et al, 1985; Mountain et
al, 1991).
Separating patients into smokers and non-smokers, a significant
difference between tumour and control Cath H levels appeared
only within the former group, whereas for non-smokers Cath H
remained unchanged. This is the first evidence indicating associa-
tion of Cath H expression or regulation with cigarette smoking in
human lung cancer and is consistent with previous studies
revealing an increase of Cath B and L activity in lung tissue of
smokers (Knoch et al, 1994; Werle et al, 1995), in their alveolar
macrophages and alveolar lavage fluid (Chang et al, 1986;
Takahashi et al, 1993) as well as in alveolar macrophages and
bronchoalveolar lavage fluid of rats exposed to cigarette smoke
(Gairola et al, 1989; Lesser et al, 1989; Chapman et al, 1997).
Furthermore, Yukio Ishii (1991a, 1991b) clearly demonstrated that
Cath H is secreted mainly with surfactant from Type II alveolar
epithelial cells and alveolar macrophages of rat lung. This report
strongly indicates a different role of Cath H from those of Cath B
and Cath L. In fact, contrary to Cath H, the overexpression of Cath
B and Cath L has been reported in lung tumours as well as in
several other studies of aetiologically different cancers (reviewed
by Kos et al, 1998). Although Cath B, L and H are all lysosomal
cysteine peptidases, large variations in expression of individual
cathepsins in different tissues (Qian et al, 1991) and even in
Cathepsin H in lung tumours 785
British Journal of Cancer (2000) 82(4), 782–788 © 2000 Cancer Research Campaign
Squamous
(P = 0.001)
Adeno Large-cell
(P = 0.028)
Carcinoid Small-cell Secondary
tumour
0
100
200
300
400
500
600
700
800
C
a
t
h
 
H
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
 
m
g
–
1
 
p
r
o
t
e
i
n
)
Figure 1 Cath H levels in matched pairs of lung parenchyma (n n) and
tumour tissues ( ). The bold line in the box is the median value. The top
and the bottom of the box represent 25th and 75th percentiles, respectively,
and the ends of the bars represent the 5th and 95th percentiles
Figure 2 Cath H levels in matched pairs of lung parenchyma (n n) and
tumour tissues ( ) of non-smokers, ex-smokers and smokers. The bold line
in the box is the median value. n represents the number of patients in the
sub-group. The top and the bottom of the box represent 25th and 75th
percentiles, respectively, and the ends of the bars represent the 5th and 95th
percentiles
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different types of cells within the same tissue (Uchiyama et al,
1994) have been reported. Selective expression of individual
peptidases in different types of tumour suggest that they may
participate in specialized cellular functions (San Segundo et al,
1986; Chapman et al, 1997). Distinct function of these enzymes
could result from the differences in their structure. In contrast to
Cath L, which is the most powerful endopeptidase, and Cath B,
which possesses endopeptidase and exopeptidase activity, Cath H
acts mainly as exo(amino) peptidase (Koga et al, 1992; Kirschke et
al, 1995). The linkage between the enzymatic properties of
cysteine peptidases and their differential function in human lung 
as well as in cancer progression is not known. With the ELISA
technique, we determined not only mature Cath H but also its
proform and complexed Cath H molecules. The active enzyme
status of Cath H in lung tissues and lung tumours might provide
further information including correlation with lung diseases and
cancer.
Since the difference in Cath H levels between non-tumourous
lung parenchyma and tumours appeared in the group of smokers
and not in the non-smokers, one may speculate that the level of
Cath H expression is not mainly influenced by malignant progres-
sion but by the effects of cigarette smoking. A similar observation
has been found for carcinoembryonic antigen (CEA) m-RNA
levels in control and tumour lung tissues (Ohwada et al, 1995). On
the other hand, extracellular levels of Cath H, being significantly
increased and correlating with the stage of malignancy in breast,
colorectal and melanoma cancers (Gabrijelc ˘ic ˘ et al, 1992; Kos
et al, 1997), identify this enzyme as being active in tumour
progression. Serum levels of Cath H determined in lung cancer
patients clearly confirm the latter observations. Cath H levels were
raised in sera of patients of all histological types, being the highest
for SCLC and SCC. Patients suffering from benign lung diseases
expressed lower levels of serum Cath H than patients with malig-
nant tumours, but still significantly higher than those in healthy
controls. Our results, revealing unchanged or decreased levels of
Cath H in tumour tissues and increased levels in patients’ sera,
support the possibility that the secretion of Cath H is enhanced in
lung tumours.
Lung tumours are very heterogeneous, expressing different
metastatic abilities and then respond differently to chemo- and
radiotherapy (Manegold and Drings, 1998; Schraube et al, 1998).
Overall survival probability rate is very poor for patients with
SCLC (Schiller, 1998). For patients with NSCLC the histological
type and the tumour stage (pTNM) of the lung tumours are the
most relevant prognostic indicators. However, within the groups of
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Figure 3 Cath H levels in sera of patients with lung tumours and healthy controls. Error bars represent mean ± 2 s.e.m
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Figure 4 Prognostic significance of Cath H within the group of smokers. A
cut-off value of 349 ng mg–1 protein to divide patients into low- (         Cath H
< 349 ng mg–1 prot.) and high-          Cath H ³ 349 ng mg–1 prot.) groupspatients with low tumour stage, new prognostic factors are still
needed to discriminate between high- and low-risk patients. Cath
B has been shown to be a significant prognostic marker for
NSCLC at enzyme activity (Ebert et al, 1994; Knoch et al, 1994;
Werle et al, 1997b), and immunohistochemical levels (Inoue et al,
1994; Sukoh et al, 1994). Cath L and specific cysteine peptidase
inhibitor stefin B have also been shown to be prognostic factors in
lung cancer patients (Ebert et al, 1997; Werle et al, 1997a). In the
most recent study Cath B immunostaining was demonstrated as a
strong, independent prognostic factor in patients with SCC (Werle
et al, 1999a).
For Cath H we found no significant correlation between tumour
levels and survival when in the entire patient population was
analysed. However, in the subgroup of smokers, Cath H levels
correlated with the survival probability rate. Thus, cigarette
smoking and high level of tumour Cath H may predict high risk of
death in lung cancer patients.
In conclusion, in lung tumours Cath H shows a different behav-
iour from other cysteine peptidases, e.g. Cath B or Cath L. Its
levels were lower in tumours but significantly higher in sera of
lung cancer patients, suggesting either its lower expression or
enhanced secretion or both. The prognostic impact of Cath H
concentration in lung cancer is rather low and this is in agreement
with the lack of correlation with the clinical and pathological para-
meters that indicate progression of lung cancer. However, the asso-
ciation of Cath H and cigarette smoking revealed a significantly
increased risk of death in lung cancer patients and indicates the
involvement of Cath H in tobacco-induced carcinogenesis.
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